Summary

Eligibility
for people ages 21-70 (full criteria)
Location
at UCSD
Dates
study started
study ends around
Principal Investigator
by Cory R Weissman, MD, PhD (ucsd)

Description

Summary

Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.

Official Title

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]

Details

Physician burnout is a critical issue. Research shows that physician burnout is increasing, that physicians suffer higher rates of burnout than the general population, and that physician burnout is associated with poor mental health outcomes.

Psilocybin is a naturally occurring alkaloid within certain fungi that elicits acute perceptual, cognitive, and emotional changes when ingested, due to action on neurotransmitter and neurocirculatory systems. The combination of psilocybin with psychological support, termed Psilocybin-Assisted Therapy (PAT), is a promising new mental health intervention shown to produce rapid and sustained improvements in psychological domains affected in burnout. PAT demonstrates preliminary efficacy as a treatment for depression and substance use disorders, is associated with brain changes measured with electroencephalography (EEG) and is a strong candidate treatment for physician burnout.

The primary aim is to assess whether incorporating biofeedback of interpersonal synchrony and individual biosignal biofeedback measures can enhance PAT outcomes. This will be determined by the superiority in the reduction of pre- and post-treatment burnout subscale scores of the biofeedback arm compared to the standard PAT arm. The secondary aim is to confirm the safety, tolerability, and efficacy of PAT to reduce burnout symptoms in physicians. In addition to these aims, exploratory analyses will examine neurophysiological and behavioral measures (e.g., EEG and multimodal synchrony) to evaluate their associations with clinical outcomes and identify potential biomarkers of response to psilocybin-assisted therapy.

Keywords

Burnout, Burnout, Healthcare Workers, physician, doctor, psilocybin, biofeedback, electroencephalography, psychotherapy, synchrony, professional fulfillment, dyadic, neurofeedback, Psychological Burnout, Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Real-time Biofeedback

Eligibility

You can join if…

Open to people ages 21-70

  1. Faculty physician, aged 21-70. Volunteer faculty are not included
  2. Meets criteria for physician burnout
  3. Experiencing symptoms of burnout for >6 months
  4. Able to complete all required study visits
  5. Not previously diagnosed with a serious mental illness (including schizophrenia, bipolar disorder, and severe depression), or substance use disorder as confirmed in clinical interview
  6. Not currently taking any psychotropic medications or nonpsychotropic medication that may be associated with serotonin syndrome, such as serotonin reuptake inhibitors (SSRI or SNRI), dextromethorphan, linezolid, tramadol, meperidine

You CAN'T join if...

  1. Previous inpatient psychiatric hospitalization(s)
  2. Previously diagnosed with a psychotic disorder (schizophrenia, schizoaffective disorder, or other psychotic spectrum disorder), bipolar spectrum disorder, personality disorder (borderline personality disorder, antisocial personality disorder, or other severe personality disorders), any severe psychiatric disorder.
  3. Exhibiting elevated suicide risk
  4. First degree family history of psychosis or bipolar disorder
  5. Prior exposure to psilocybin or other psychedelic compounds in the previous 5 years
  6. Currently pregnant, nursing, planning pregnancy, engaging in sexual intercourse without effective contraceptive method in last three months
  7. Those who plan to donate sperm within three months following the study.
  8. Known cardiovascular disease including history of stroke, myocardial infarction, uncontrolled hypertension, valvular heart disease, tachycardia, elongated QT interval, or clinically significant arrythmia.
  9. History of seizure disorder
  10. Use of recreational illicit drugs
  11. Clinically concerning results from vital signs, ECG, physical examination, or laboratory tests during screening
  12. Any other clinically significant illnesses deemed to pose risk for the participant

Location

  • UC San Diego accepting new patients
    San Diego California 92037 United States

Lead Scientist at University of California Health

  • Cory R Weissman, MD, PhD (ucsd)
    Associate Professor Of Clinical, Psychiatry, Vc-health Sciences-schools. Authored (or co-authored) 45 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT06814522
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated